Jim Cramer on Eli Lilly: “It’s Become Luckless”

Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated:

“How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t have a new use for Zepbound, the revolutionary GLP-1 drug, or announce the date for the pill version, the stock’s going to pull back to the $700s from its current $825 level. It can’t get out of its own way.”

Pixabay/Public Domain

Eli Lilly and Company (NYSE:LLY) develops prescription medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic diseases. A caller inquired about the stock during the October 21 episode, and Cramer responded:

“Here’s the problem with Lilly: they need to have something else to come out. They need something that’s big that the insurance companies will cover, for their drug, because right now, a lot of people just feel, you know what, this Ozempic thing, it’s played out. If you get something else, a new indication, that will ignite the stock.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.